Canaccord Genuity reiterates a 'Buy' on Synta Pharmaceuticals (NASDAQ: SNTA), PT $8.

Canaccord analyst says, "We reiterate our rating on ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE